Symptomatology of carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy.

ABSTRACT:

Objective

To ascertain whether adverse effects experienced by people taking carbamazepine or oxcarbazepine could be attributed to carbamazepine- or oxcarbazepine-induced hyponatremia (COIH).

Methods

We performed an observational study, collecting data between 2017 and 2019 on serum sodium levels and adverse effects retrospectively in people with epilepsy while receiving treatment with either carbamazepine (CBZ) or oxcarbazepine (OXC). We defined hyponatremia as sodium level ≤134 mEq/L and severe hyponatremia as sodium level ≤128 mEq/L. Adverse effects experienced were compared between groups of individuals with and without hyponatremia.

Results

A total of 1370 people using CBZ or OXC were identified, of whom 410 had at least one episode of hyponatremia. We checked for

SUBMITTER: Berghuis B 

PROVIDER: S-EPMC8248112 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature